Logo.png
Cocrystal Pharma Reports 2021 Financial Results and Provides Updates on Development Programs and Milestones
23 mars 2022 16h05 HE | Cocrystal Pharma, Inc.
Commenced enrollment in Phase 1 trial with orally administered, broad-spectrum antiviral agent CC-42344 for the treatment of pandemic and seasonal influenza AAdvanced COVID-19 programs with the goal...